Pharmaceuticals

CT-996 shows remarkable effect on weight loss in patients with obesity and type 2 diabetes

bexib
By bexib 0 Min Read

Treatment with CT-996 reduced placebo-adjusted mean body weight by 6.1% within four weeks in participants who were obese but did not have type 2 diabetes.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Weekly initial unemployment claims rise to 243,000
Next Article VeChain Wallet VeWorld Adds Support for Apple Pay with Transak Integration – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Do this competitive analysis before launching your idea
Retail & E-commerce
Ford Mustang Mach-E battery production moves to Michigan
Manufacturing
Wolf Richter: After wasting $64 billion on stock buybacks, Boeing launches $22 billion stock offering to give Dodge junk credit rating a breather
Economy
Become the most important part of Make
Manufacturing